Oncology Therapeutics
Replimune news and milestones
Replimune: 9 headlines on record, 5 headlines in the last 90 days. Its story counts 1 milestone.
Data updated Nov 15, 2026 · Back to the company report
9Headlines
5In 90 days
1Milestones
Headlines
Sep 282026
Sep 242026
News · Replimune stock falls 3.79 percent as losses persist
Replimune stock was quoted at USD 12.96 on Nasdaq on September 23, 2026. Fiscal Q1 EPS was USD 0.72 negative versus a USD 0.69 consensus loss.
Sep 232026
News · Replimune stock gains as share authorization doubles
Replimune stock faces a 300 million share authorization after September 15, 2026. The clinical-stage company reported a USD 297.0 million loss.
Sep 212026
News · BioSpace
Delivering therapeutics directly to tumors, as in the case of Replimune's recently approved Tudriqev and Amgen's Imlygic, holds advantages, especially when cancer is caught early…
Sep 32026
News · markets.businessinsider.com
WOBURN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the ...
Aug 42026
News · YahooFinance
The brokerage expects Replimune's RP1 drug to see strong demand if approved, citing its relative ease of access and favorable safety profile.
May 302026
May 292026
News · STAT
The WHO identified three drugs that should be fast-tracked through clinical testing to respond to the current Ebola outbreak
Aug 14, 20252025
News · wsj.com
Sources: the outlets named on each headline, each story once
Milestones
2015
Founded
Each milestone is dated by its source: registers, filings, the press
How to cite
Replimune, News. Alion, Nov 15, 2026. https://alion.io/company/replimune/news